|
1
|
Kurzman ID, MacEwen EG, Rosenthal RC, Fox
LE, Keller ET, Helfand SC, Vail DM, Dubielzig RR, Madewell BR,
Rodriguez CO Jr, et al: Adjuvant therapy for osteosarcoma in dogs:
Results of randomized clinical trials using combined
liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer
Res. 1:1595–1601. 1995.PubMed/NCBI
|
|
2
|
Meyers PA, Schwartz CL, Krailo M,
Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W,
Gebhardt M, Goorin AM, et al: Osteosarcoma: A randomized,
prospective trial of the addition of ifosfamide and/or muramyl
tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J
Clin Oncol. 23:2004–2011. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fan TM, Charney SC, de Lorimier LP,
Garrett LD, Griffon DJ, Gordon-Evans WJ and Wypij JM: Double-blind
placebo-controlled trial of adjuvant pamidronate with palliative
radiotherapy and intravenous doxorubicin for canine appendicular
osteosarcoma bone pain. J Vet Intern Med. 23:152–160. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Goldsby RE, Fan TM, Villaluna D, Wagner
LM, Isakoff MS, Meyer J, Randall RL, Lee S, Kim G, Bernstein M, et
al: Feasibility and dose discovery analysis of zoledronic acid with
concurrent chemotherapy in the treatment of newly diagnosed
metastatic osteosarcoma: A report from the Children's Oncology
Group. Eur J Cancer. 49:2384–2391. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhao J, Xu H, He M, Wang Z and Wu Y: Rho
GTPase-activating protein 35 rs1052667 polymorphism and
osteosarcoma risk and prognosis. Biomed Res Int. 2014:3969472014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tóth C, Meinrath J, Herpel E, Derix J,
Fries J, Buettner R, Schirmacher P and Heikaus S: Expression of the
apoptosis repressor with caspase recruitment domain (ARC) in liver
metastasis of colorectal cancer and its correlation with DNA
mismatch repair proteins and p53. J Cancer Res Clin Oncol.
142:927–935. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Deorukhkar A, Ahuja N, Mercado AL,
Diagaradjane P, Raju U, Patel N, Mohindra P, Diep N, Guha S and
Krishnan S: Zerumbone increases oxidative stress in a
thiol-dependent ROS-independent manner to increase DNA damage and
sensitize colorectal cancer cells to radiation. Cancer Med.
4:278–292. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Véquaud E, Desplanques G, Jézéquel P, Juin
P and Barillé-Nion S: Survivin contributes to DNA repair by
homologous recombination in breast cancer cells. Breast Cancer Res
Treat. 155:53–63. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang XW, Jiang JF and Xu B:
Differentiation-inducing action of 10-hydroxycamptothecin on human
hepatoma Hep G2 cells. Acta Pharmacol Sin. 21:364–368.
2000.PubMed/NCBI
|
|
10
|
Hu W, Zhang C, Fang Y and Lou C:
Anticancer properties of 10-hydroxycamptothecin in a murine
melanoma pulmonary metastasis model in vitro and in vivo. Toxicol
In Vitro. 25:513–520. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wei W, Shi SJ, Liu J, Sun X, Ren K, Zhao
D, Zhang XN, Zhang ZR and Gong T: Lipid nanoparticles loaded with
10-hydroxycamptothecin-phospholipid complex developed for the
treatment of hepatoma in clinical application. J Drug Target.
18:557–566. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yuan ZF, Tang YM, Xu XJ, Li SS and Zhang
JY: 10-Hydroxycamptothecin induces apoptosis in human neuroblastoma
SMS-KCNR cells through p53, cytochrome c and caspase 3 pathways.
Neoplasma. 63:72–79. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gallegos-Castorena S, Martínez-Avalos A,
Mohar-Betancourt A, Guerrero-Avendaño G, Zapata-Tarrés M and
Medina-Sansón A: Toxicity prevention with amifostine in pediatric
osteosarcoma patients treated with cisplatin and doxorubicin.
Pediatr Hematol Oncol. 24:403–408. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Navid F, Santana VM, Neel M, McCarville
MB, Shulkin BL, Wu J, Billups CA, Mao S, Daryani VM, Stewart CF, et
al: A phase II trial evaluating the feasibility of adding
bevacizumab to standard osteosarcoma therapy. Int J Cancer.
141:1469–1477. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang Z, Luo X, Zhang X, Liu J and Jiang Q:
Targeted delivery of 10-hydroxycamptothecin to human breast cancers
by cyclic RGD-modified lipid-polymer hybrid nanoparticles. Biomed
Mater. 8:0250122013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang X, Gan Y, Gan L, Nie S and Pan W:
PEGylated nanostructured lipid carriers loaded with
10-hydroxycamptothecin: An efficient carrier with enhanced
anti-tumour effects against lung cancer. J Pharm Pharmacol.
60:1077–1087. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Carvalho S, Vitor AC, Sridhara SC, Martins
FB, Raposo AC, Desterro JM, Ferreira J and de Almeida SF: SETD2 is
required for DNA double-strand break repair and activation of the
p53-mediated checkpoint. Elife. 3:e024822014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dutta S, Warshall C, Bandyopadhyay C,
Dutta D and Chandran B: Interactions between exosomes from breast
cancer cells and primary mammary epithelial cells leads to
generation of reactive oxygen species which induce DNA damage
response, stabilization of p53 and autophagy in epithelial cells.
PLoS One. 9:e975802014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Simone CB II, John-Aryankalayil M,
Palayoor ST, Makinde AY, Cerna D, Falduto MT, Magnuson SR and
Coleman CN: mRNA expression profiles for prostate cancer following
fractionated irradiation are influenced by p53 status. Transl
Oncol. 6:573–585. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Uchiumi F, Watanabe T, Ohta R, Abe H and
Tanuma S: PARP1 gene expression is downregulated by knockdown of
PARG gene. Oncol Rep. 29:1683–1688. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Halder AK, Saha A, Saha KD and Jha T:
Stepwise development of structure-activity relationship of diverse
PARP-1 inhibitors through comparative and validated in silico
modeling techniques and molecular dynamics simulation. J Biomol
Struct Dyn. 33:1756–1779. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dawicki-McKenna JM, Langelier MF, DeNizio
JE, Riccio AA, Cao CD, Karch KR, McCauley M, Steffen JD, Black BE
and Pascal JM: PARP-1 activation requires local unfolding of an
autoinhibitory domain. Mol Cell. 60:755–768. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hu H, Jiang C, Ip C, Rustum YM and Lü J:
Methylseleninic acid potentiates apoptosis induced by
chemotherapeutic drugs in androgen-independent prostate cancer
cells. Clin Cancer Res. 11:2379–2388. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou J, Wu S, Chen Y, Zhao J, Zhang K,
Wang J and Chen S: microRNA-143 is associated with the survival of
ALDH1+CD133+ osteosarcoma cells and the chemoresistance of
osteosarcoma. Exp Biol Med (Maywood). 240:867–875. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ye Z, Jingzhong L, Yangbo L, Lei C and
Jiandong Y: Propofol inhibits proliferation and invasion of
osteosarcoma cells by regulation of microRNA-143 expression. Oncol
Res. 21:201–207. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kwon HY, Kim KS, An HK, Moon HI, Kim HJ
and Lee YC: Triptolide induces apoptosis through extrinsic and
intrinsic pathways in human osteosarcoma U2OS cells. Indian J
Biochem Biophys. 50:485–491. 2013.PubMed/NCBI
|
|
27
|
Li J, Zhang F and Wang S: A polysaccharide
from pomegranate peels induces the apoptosis of human osteosarcoma
cells via the mitochondrial apoptotic pathway. Tumour Biol.
35:7475–7482. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun Z, Huang K, Fu X, Zhou Z, Cui Y and Li
H: A chemically sulfated polysaccharide derived from Ganoderma
lucidum induces mitochondrial-mediated apoptosis in human
osteosarcoma MG63 cells. Tumour Biol. 35:9919–9926. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chipoy C, Brounais B, Trichet V, Battaglia
S, Berreur M, Oliver L, Juin P, Rédini F, Heymann D and Blanchard
F: Sensitization of osteosarcoma cells to apoptosis by oncostatin M
depends on STAT5 and p53. Oncogene. 26:6653–6664. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Roepke M, Diestel A, Bajbouj K,
Walluscheck D, Schonfeld P, Roessner A, Schneider-Stock R and
Gali-Muhtasib H: Lack of p53 augments thymoquinone-induced
apoptosis and caspase activation in human osteosarcoma cells.
Cancer Biol Ther. 6:160–169. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cao X, Bennett RL and May WS: c-Myc and
caspase-2 are involved in activating Bax during cytotoxic
drug-induced apoptosis. J Biol Chem. 283:14490–14496. 2008.
View Article : Google Scholar : PubMed/NCBI
|
